Takeda and AMAG Receive A Positive CHMP Opinion in Europe for Rienso® (ferumoxytol) for the Treatment of Iron Deficiency Anaemia in Adult Chronic Kidney Disease Patients


London, UK, April 20, Osaka, Japan, April 23 and Lexington, MA, USA April 20 – Takeda Pharmaceutical Company Limited (Takeda) and AMAG Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for ferumoxytol, a new intravenous (IV) iron therapy with a proposed indication for the treatment of iron deficiency anaemia (IDA) in adult patients with chronic kidney disease (CKD).

Read more


Top of page

Takeda Pharma